Piperlongumine downregulates the expression of HER family in breast cancer cells.
Biochem Biophys Res Commun
; 486(4): 1083-1089, 2017 05 13.
Article
in En
| MEDLINE
| ID: mdl-28377224
ABSTRACT
HER family receptors are frequently deregulated in breast cancer and the deregulation of these receptors is associated with poor prognosis. Thus, these receptors are considered therapeutic targets. In the present study, we found that piperlongumine (PL) downregulates the expression of HER family receptors HER1, HER2, and HER3 in breast cancer cells. Downregulation of these receptors by PL is mediated through the generation of reactive oxygen species (ROS), as N-acetyl-cysteine blocks it. Interestingly, the HER2-overexpressing cell lines BT474 and SkBr3 are somewhat more sensitive to PL than the low HER2-expressing cell line MCF7. In addition, the overexpression of HER2 increases the sensitivity of MCF7 cells to PL. Collectively, our data indicate the therapeutic potential of PL in the treatment of breast cancer.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Gene Expression Regulation, Neoplastic
/
Reactive Oxygen Species
/
Dioxolanes
/
ErbB Receptors
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Biochem Biophys Res Commun
Year:
2017
Document type:
Article